GSK’s systemic STING agonist could overcome delivery hurdles
Editor's Note: This article was updated on Nov 08, 2018 at 4:05 PM PST
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) researchers have developed a STING agonist that can be delivered systemically as opposed to intratumorally, which can overcome challenges of accessing hard to reach tumors or cancers that have spread.
At least two companies have unencapsulated compounds that activate STING (TMEM173), which triggers CD8+ T cells to initiate tumor cell killing, in clinical testing. Merck & Co. Inc. (NYSE:MRK) and Aduro Biotech Inc. (NASDAQ:ADRO) each have...
Read the full 330 word article
User Sign in
Trial Subscription
Get a 4-week free trial subscription to BioCentury Extra
Article Purchase
$50 USD
